For the quarter ending 2026-03-31, SNDX had -$4,037K decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -42,673 | -68,014 | -60,715 | -156,693 |
| Depreciation | 4 | 3 | 3 | 0 |
| Accretion of investments | 862 | 1,530 | 2,413 | 6,810 |
| Non-cash operating lease expense | 130 | 395 | 158 | 393 |
| Stock-based compensation | 12,054 | 11,254 | 12,082 | 24,167 |
| Amortization of debt issuance costs | 56 | -1 | 62 | 167 |
| Provision for credit losses | - | 0 | 3,667 | - |
| Inventory reserves | - | 163 | - | - |
| Accounts receivable, net | -120 | 12,593 | 5,949 | 11,852 |
| Inventory, net | 2,060 | 7,801 | 7,183 | 17,107 |
| Prepaid expenses and other assets | -7,837 | 5,400 | 4,364 | 4,778 |
| Collaboration receivable (payable), net | 3,238 | -8,009 | -3,420 | -31,547 |
| Other receivable | -6,137 | 6,404 | 38 | -6 |
| Other assets | - | 0 | 0 | - |
| Accounts payable | -5,737 | 2,754 | -3,527 | 5,727 |
| Accrued expenses and other liabilities | -28,349 | 25,695 | 1,102 | 15,370 |
| Net cash used in operating activities | -50,345 | -69,488 | -70,535 | -182,957 |
| Purchases of property and equipment | - | 56 | 131 | - |
| Purchases of short and long-term investments | 39,387 | 63,116 | 30,440 | 102,251 |
| Proceeds from sales and maturities of short-term investments | 77,777 | 144,750 | 103,000 | 238,280 |
| Net cash provided by investing activities | 38,390 | 81,578 | 72,429 | 136,029 |
| Proceeds from issuance of common stock in follow-on public stock offering, net-Follow On Public Offerings | - | 0 | - | - |
| Proceeds from issuance of common stock in follow-on public stock offering, net-At The Market Stock Offering | - | 0 | - | - |
| Proceeds from purchase and sale agreement, net | - | 0 | - | - |
| Proceeds from employee stock purchase plan | 458 | 605 | -80 | 1,013 |
| Proceeds from stock option exercises | 7,460 | 5,312 | 6,358 | 468 |
| Net cash provided by financing activities | 7,918 | 5,917 | 6,278 | 1,481 |
| Net decrease cash, cash equivalents and restricted cash | -4,037 | 18,007 | 8,172 | -45,447 |
| Cash, cash equivalents and restricted cashbeginning of period | 135,032 | 0 | 154,300 | - |
| Cash, cash equivalents and restricted cash end of period | 130,995 | 135,032 | 117,025 | - |
Syndax Pharmaceuticals Inc (SNDX)
Syndax Pharmaceuticals Inc (SNDX)